

Resource Summary Report

Generated by [dkNET](#) on Aug 16, 2026

Ki-67

RRID:AB_10611571

Type: Antibody

Proper Citation

BD Biosciences Cat# 561277, RRID:AB_10611571

Antibody Information

URL: http://antibodyregistry.org/AB_10611571

Proper Citation: BD Biosciences Cat# 561277, RRID:AB_10611571

Target Antigen: Ki-67

Host Organism: mouse

Clonality: monoclonal

Comments: Intracellular staining (flow Cytotoxicityometry)

Antibody Name: Ki-67

Description: This monoclonal targets Ki-67

Target Organism: human

Antibody ID: AB_10611571

Vendor: BD Biosciences

Catalog Number: 561277

Record Creation Time: 20250819T231603+0000

Record Last Update: 20250820T044845+0000

Ratings and Alerts

- This antibody has been included in the HuBMAP's Organ Mapping Antibody Panels, please see specific validation data: <https://avr.hubmapconsortium.org> See: Human_Liver_Manual_IBEX.xlsx - The Human BioMolecular Atlas Program

No alerts have been found for Ki-67.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 50 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Freeburg NF, et al. (2026) The critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM. Cell.

Moro A, et al. (2025) Growth of human regulatory CD4+ T cells is more tightly controlled than effector T cells due to distinctive molecular programming. iScience, 28(6), 112553.

Karaliota S, et al. (2025) Highly immunogenic DNA/LION nanocarrier vaccine potently activates lymph nodes inducing long-lasting immunity in macaques. iScience, 28(4), 112232.

Humblin E, et al. (2025) The costimulatory molecule ICOS limits memory-like properties and function of exhausted PD-1+CD8+ T cells. Immunity, 58(8), 1966.

Champiat S, et al. (2025) Nanrilkefusp alfa (SOT101), an IL-15 receptor ?? superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers. Cell reports. Medicine, 6(2), 101967.

Broderick C, et al. (2025) A RAS(ON) Multi-Selective Inhibitor Combination Therapy Triggers Long-term Tumor Control through Senescence-Associated Tumor-Immune Equilibrium in Pancreatic Ductal Adenocarcinoma. Cancer discovery, 15(8), 1717.

Hahn PA, et al. (2025) Exogenous estrogen enhances T cell activation in male primates. Cell reports, 44(9), 116170.

Li S, et al. (2025) Protocol for multiplex immunofluorescence imaging of mouse intestinal tumors. STAR protocols, 6(2), 103776.

Murphy MK, et al. (2025) The transcriptional repressor BLIMP1 enforces TCF-1-dependent and -independent restriction of the memory fate of CD8+ T cells. Immunity, 58(10), 2472.

You S, et al. (2024) Lymphatic-localized Treg-mregDC crosstalk limits antigen trafficking and restrains anti-tumor immunity. Cancer cell, 42(8), 1415.

Lin F, et al. (2024) Multimodal targeting chimeras enable integrated immunotherapy leveraging tumor-immune microenvironment. Cell, 187(26), 7470.

Englebert K, et al. (2024) The CD27/CD70 pathway negatively regulates visceral adipose tissue-resident Th2 cells and controls metabolic homeostasis. *Cell reports*, 43(3), 113824.

Müller TR, et al. (2024) Memory T cells effectively recognize the SARS-CoV-2 hypermutated BA.2.86 variant. *Cell host & microbe*, 32(2), 156.

Pulliam T, et al. (2024) Circulating cancer-specific CD8 T cell frequency is associated with response to PD-1 blockade in Merkel cell carcinoma. *Cell reports. Medicine*, 5(2), 101412.

Shouse AN, et al. (2024) Interleukin-2 receptor signaling acts as a checkpoint that influences the distribution of regulatory T cell subsets. *iScience*, 27(12), 111248.

Radtke AJ, et al. (2024) Multi-omic profiling of follicular lymphoma reveals changes in tissue architecture and enhanced stromal remodeling in high-risk patients. *Cancer cell*, 42(3), 444.

Wang G, et al. (2024) Adipose-tissue Treg cells restrain differentiation of stromal adipocyte precursors to promote insulin sensitivity and metabolic homeostasis. *Immunity*, 57(6), 1345.

Anderson TM, et al. (2024) FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(9), 1758.

Wang K, et al. (2024) Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8⁺ T cells. *Cancer cell*, 42(9), 1582.

Gaglia G, et al. (2023) Lymphocyte networks are dynamic cellular communities in the immunoregulatory landscape of lung adenocarcinoma. *Cancer cell*, 41(5), 871.